Contrasting immune responses mediate Campylobacter jejuni-induced colitis and autoimmunity

Mucosal Immunology

Volumn 7, Issue 4, 2014, Pages 802-817

  Malik, A ^a,b   Sharma, D ^b   St Charles, J ^a   Dybas, L A ^a   Mansfield, L S ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GANGLIOSIDE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; RAG1 PROTEIN; BACTERIUM ANTIBODY; CYTOKINE; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BACTERIAL STRAIN; CAMPYLOBACTER JEJUNI; CELL INFILTRATION; COLITIS; CONTROLLED STUDY; CROSS REACTION; GUILLAIN BARRE SYNDROME; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOID CELL; MOUSE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN DEPLETION; T LYMPHOCYTE; UPREGULATION; ANIMAL; CAMPYLOBACTERIOSIS; CELLULAR IMMUNITY; DEFICIENCY; DISEASE MODEL; GENE REARRANGEMENT; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; METABOLISM; MICROBIOLOGY; SEVERITY OF ILLNESS INDEX; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, BACTERIAL; AUTOIMMUNITY; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNITY, CELLULAR; IMMUNITY, INNATE; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; INTERLEUKIN-10; MICE; MICE, KNOCKOUT; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS;

EID: 84902578878     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.97     Document Type: Article

References (52)

1. CDC. Incidence of laboratory-confirmed bacterial and parasitic infections, and postdiarrheal hemolytic uremic syndrome (HUS), by year and pathogen http://www.cdc.gov/foodnet/data/trends/tables/table2ab. html#table-2b 1996-2011 (2012
2. Dasti, J.I., Tareen, A.M., Lugert, R, Zautner, A.E. &Gro, U. Campylobacter jejuni: A brief overview on pathogenicity-Associated factors and diseasemediating mechanisms. Int. J. Med. Microbiol. 300, 205-211 (2010
3. Butzler, J. P. Campylobacter, from obscurity to celebrity. Clin. Microbiol. Infect. 10, 868-876 (2004
4. van Spreeuwel, J. P. et al. Campylobacter colitis: Histological immunohistochemical and ultrastructural findings. Gut 26, 945-951 (1985
5. Blaser, M. J. Epidemiologic and clinical features of Campylobacter jejuni infections. J. Infect. Dis. 176, S103-S105 (1997
6. Tee, W & Mijch, A. Campylobacter jejuni bacteremia in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: Comparison of clinical features and review. Clin. Infect. Dis. 26, 91-96 (1998
7. Gradel, K. O. et al. Increased short- And long-Term risk of inflammatory bowel disease after Salmonella or Campylobacter gastroenteritis. Gastroenterology 137, 495-501 (2009
8. Qin, H-Y. et al. Systematic review of animal models of post-infectious/ post-inflammatory irritable bowel syndrome. J. Gastroenterol. 46, 164-174 (2011
9. Garg, A. X., Pope, J. E., Thiessen-Philbrook, H, Clark, W. F. & Ouimet, J. Arthritis risk after acute bacterial gastroenteritis. Rheumatology 47, 200-204 (2008
10. Yuki, N. et al. Association of IgG anti-GD1a antibody with severe Guillain-Barré syndrome. Muscle Nerve 16, 642-647 (1993
11. Vucic, S, Kiernan, M. C. & Cornblath, D. R. Guillain-Barré syndrome: An update. J. Clin. Neurosci. 16, 733-741 (2009
12. Hughes, R. A. & Cornblath, D. R. Guillain-Barre syndrome. Lancet 366, 1653-1666 (2005
13. CDC. Gullian Barre Syndrome http://www.cdc.gov/flu/protect/vaccine/ guillainbarre.htm2012
14. Jacobs, B. C. et al. Campylobacter jejuni infections and anti-GM1 antibodies in guillain-barré syndrome. Ann. Neurol. 40, 181-187 (1996
15. Islam, Z. et al. Guillain-Barré syndrome-related Campylobacter jejuni in Bangladesh: Ganglioside mimicry and cross-reactive Aatibodies. PLoS One 7, e43976 (2012
16. Goodfellow, J. A. et al. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J. Neurosci. 25, 1620-1628 (2005
17. Kieseier, B. C. et al. Advances in understanding and treatment of immunemediated disorders of the peripheral nervous system. Muscle Nerve 30, 131-156 (2004
18. Ouyang, W, Rutz, S, Crellin, N. K., Valdez, P. A. & Hymowitz, S. G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29, 71-109 (2011
19. Saraiva, M & O'Garra, A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10, 170-181 (2010
20. Franke, A. et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 40, 1319-1323 (2008
21. Mansfield, L. S. et al. C57BL/6 and congenic interleukin-10-deficient mice can serve as models of Campylobacter jejuni colonization and enteritis. Infect. Immunity 75, 1099-1115 (2006
22. Mansfield, L. et al. Genetic background of IL-10-/- mice alters host-pathogen interactions with Campylobacter jejuni and influences disease phenotype. Microbial Pathogenesis 45, 241-257 (2008
23. Mansfield, L. et al. Animal models of Campylobacter jejuni infections. Campylobacter, 3rd edn. 367-379 (ASM Press, Washington, DC, 2008
24. Bell, J. A. et al. Outcome of infection of C57BL/6 IL-10(-/-) mice with Campylobacter jejuni strains is correlated with genome content of open reading frames up- And down-regulated in vivo. Microbial. Pathogenesis 54, 1-19 (2013
25. Bell, J. A. et al. Multiple factors interact to produce responses resembling spectrum of human Disease in Campylobacter jejuni infected C57BL/6 IL-10-/- mice. BMC Microbiol. 9, 57 (2009
26. Bereswill, S. et al. Gnotobiotic IL-10-/-; NF-kBEGFP mice develop rapid and severe colitis following Campylobacter jejuni infection. PLoS One 4, e7413 (2009
27. Sun, X, Threadgill, D & Jobin, C. Campylobacter jejuni induces colitis through activation of mammalian target of rapamycin signaling. Gastroenterology 142 (1), 86-95.e5 (2012
28. Sun, X, Liu, B, Sartor, R. B. & Jobin, C. Phosphatidylinositol 3-kinase-g signaling promotes Campylobacter jejuni-induced colitis through neutrophil recruitment in mice. J Immunol 190, 357-365 (2013
29. Koga, M. et al. Anti-GM1 antibody IgG subclass A clinical recovery predictor in Guillain-Barré syndrome. Neurology 60, 1514-1518 (2003
30. Reinhardt, R. L., Liang, H-E. & Locksley,R.M.Cytokine-secreting follicular T cells shape the antibody repertoire. Nat. Immunol. 10, 385-393 (2009
31. Stavnezer, J. Immunoglobulin class switching. Curr Opin. Immunol. 8, 199-205 (1996
32. Deenick, E. K., Hasbold, J & Hodgkin, P. D. Decision criteria for resolving isotype switching conflicts by B cells. Eur. J. Immunol. 35, 2949-2955 (2005
33. Bai, Y. et al. CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cellmediated autoimmunity. Eur. J. Immunol. 38, 1877-1888 (2008
34. Bernink, J. H. et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat. Immunol. 14 (3), 221-229 (2013
35. Sonnenberg, G. F. & Artis, D. Innate lymphoid cell interactions with microbiota: Implications for intestinal health and disease. Immunity 37, 601-610 (2012
36. Diefenbach, A & Vonarbourg, C. Innate lymphocytes induce inflammatory bowel disease. Immunol. Cell Biol. 88, 694-696 (2010
37. Cua, D. J. & Tato, C. M. Innate IL-17-producing cells: The sentinels of the immune system. Nat. Rev. Immunol. 10, 479-489 (2010
38. Spits, H & Di Santo, J. P. The expanding family of innate lymphoid cells: Regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 12, 21-27 (2010
39. Cherrier, M, Ohnmacht, C, Cording, S & Eberl, G. Development and function of intestinal innate lymphoid cells. Curr. Opin. Immunol. 24 (3), 277-283 (2010
40. Sonnenberg, G. F., Monticelli, L. A., Elloso, M. M., Fouser, L. A. & Artis, D. CD4+ lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 34, 122-134 (2011
41. Buonocore, S. et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464, 1371-1375 (2010
42. Caramaschi, P. et al. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases. Joint Bone Spine 76, 333-342 (2009
43. Lozeron, P, Denier, C, Lacroix, C & Adams, D. Long-Term course of demyelinating neuropathies occurring during tumor necrosis factor-A-blocker therapy. Arch. Neurol. 66, 490-497 (2009
44. Tristano, A. G. Neurological adverse events associated with anti-Tumor necrosis factor alpha treatment. J. Neurol. 257, 1421-1431 (2010
45. Zhang, M. et al. Association study between an outbreak of Guillain-Barre syndrome in Jilin, China, and preceding Campylobacter jejuni infection. Foodborne Pathogens Dis. 7, 913-919 (2010
46. Kalra, V. et al. Association of Campylobacter jejuni infection with childhood Guillain-Barré syndrome: A case-control study. J. Child Neurol. 24, 664-668 (2009
47. Bax, M. et al. Campylobacter jejuni lipooligosaccharides modulate dendritic cell-mediated Tcell polarization in a sialic acid linkage-dependent manner. Infect. Immun. 79, 2681-2689 (2011
48. Huizinga, R. et al. Sialylation of Campylobacter jejuni Lipo-oligosaccharides: Impact on phagocytosis and cytokine production in mice. PLoS One 7, e34416 (2012
49. Klaas, M. et al. Sialoadhesin promotes rapid proinflammatory and type I IFN responses to a sialylated pathogen, Campylobacter jejuni. J Immunol 189, 2414-2422 (2012
50. Weigmann, B. et al. Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue. Nat. Prot. 2, 2307-2311 (2007
51. Sanos, S. L. et al. RORgt and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat. Immunol. 10, 83-91 (2008
52. Wilson, D. L., Abner, S. R., Newman, T. C., Mansfield, L. S. & Linz, J. E. Identification of ciprofloxacin-resistant Campylobacter jejuni by use of a fluorogenic PCR assay. J. Clin. Microbiol. 38, 3971-3978 (2000.